IGF-1 LR3 in Anabolic-Signaling Research: Research Reference
IGF-1 LR3 serves as a pivotal research tool for investigators elucidating anabolic signaling cascades due to its extended half-life and enhanced interaction profile with the IGF-1 receptor, circumventing native binding proteins. This unique pharmacological profile enables robust exploration of its effects on cellular growth, differentiation, and protein synthesis in a controlled laboratory setting, providing deeper insights into fundamental biological processes.
As a widely utilized compound in preclinical studies, IGF-1 LR3 facilitates detailed investigation into the mechanisms governing cellular anabolism and regeneration. Research involving this analog has contributed to a foundational understanding of growth factor biology, as evidenced by 44 indexed publications on PubMed. It is important to note that, as of the latest data, there are 0 registered studies on ClinicalTrials.gov involving IGF-1 LR3, underscoring its current status exclusively as a research-use-only compound.
Introduction to Insulin-like Growth Factor 1 (IGF-1) and its Analogs
Insulin-like Growth Factor 1 (IGF-1) stands as a pivotal polypeptide hormone, a member of the insulin superfamily, crucial for mammalian growth and development across a spectrum of physiological processes. Synthesized predominantly in the liver in response to growth hormone (GH) stimulation, IGF-1 mediates many of GH’s anabolic and mitogenic effects. Its systemic actions extend to virtually all tissues, playing integral roles in cellular proliferation, differentiation, survival, and metabolism. At a molecular level, IGF-1 exerts its functions primarily through binding to the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase, initiating a complex cascade of intracellular signaling events that underpin its multifaceted biological activities. The intricate interplay between IGF-1, its receptor, and its binding proteins (IGFBPs) orchestrates precise regulation of tissue growth and maintenance, making it a subject of extensive research in cellular biology, endocrinology, and aging studies.
The biological activity of endogenous IGF-1 is tightly modulated by a family of six high-affinity IGF-binding proteins (IGFBPs 1-6), which control its bioavailability, transport, and half-life in circulation. These binding proteins can either enhance or inhibit IGF-1’s interaction with its receptor, adding layers of complexity to its regulatory mechanisms. While essential for physiological regulation, the strong affinity of IGF-1 for IGFBPs can limit its free concentration and extend its systemic presence, posing challenges for researchers aiming to study its direct, acute effects on target cells or tissues without confounding influences. This inherent complexity has driven the development of synthetic IGF-1 analogs, designed to overcome some of these physiological constraints and provide more precise tools for dissecting IGF-1’s signaling pathways and biological functions in a controlled research environment.
Research into IGF-1 and its analogs is broad, encompassing studies focused on understanding fundamental cellular processes, tissue repair and regeneration mechanisms, and age-related decline. The development of synthetic analogs represents a significant advancement in this field, allowing researchers to explore specific aspects of IGF-1’s biology with greater clarity. These modified versions often feature structural alterations that confer altered pharmacokinetic properties, such as reduced binding to IGFBPs, increased receptor affinity, or enhanced stability, thereby offering distinct advantages for experimental applications. The ongoing exploration of these analogs contributes significantly to our understanding of growth factor biology and its implications for cellular anabolism and longevity, as evidenced by the extensive body of research peptides available for study.
For instance, the modification of the IGF-1 molecule can lead to analogs with an extended half-life or enhanced potency at the receptor level. Such characteristics are invaluable for investigators seeking to achieve sustained activation of the IGF-1 pathway in preclinical models without necessitating frequent administration or contending with rapid degradation. The careful design of these analogs allows for a more focused interrogation of IGF-1R signaling without the intricate complexities introduced by variable IGFBP concentrations, which can fluctuate in different physiological or pathological states. Thus, IGF-1 analogs serve as powerful investigative tools, enabling researchers to unravel the nuanced roles of IGF-1 in health and disease, from skeletal muscle maintenance to neuroprotection, and providing insights into potential therapeutic strategies.
IGF-1 LR3: Structural Modifications and Pharmacological Profile for Research
IGF-1 LR3, also known as Long R3 IGF-1, represents a potent and widely utilized analog of native human IGF-1, specifically engineered to enhance its utility in research settings. Its design incorporates two key structural modifications that significantly alter its pharmacological profile compared to endogenous IGF-1. Firstly, the arginine at position 3 (Arg3) has been substituted, hence “R3,” reducing its binding affinity to the majority of the circulating IGF-binding proteins (IGFBPs). This modification is crucial because it allows IGF-1 LR3 to circulate in its free, active form for a longer duration, granting it significantly increased bioavailability and an extended half-life in various biological matrices. Secondly, IGF-1 LR3 features an N-terminal 13-amino acid extension, elongating the peptide chain from 70 to 83 amino acids. This additional sequence further contributes to its altered binding characteristics and stability. The cumulative effect of these modifications makes IGF-1 LR3 a more stable and consistently active research agent for studying IGF-1 receptor signaling without the complexities introduced by endogenous IGFBP modulation.
The reduced affinity for IGFBPs is arguably the most significant functional advantage of IGF-1 LR3 in research. Endogenous IGF-1 binds tightly to IGFBPs, particularly IGFBP-3, which typically sequesters over 80% of circulating IGF-1. This binding restricts IGF-1’s access to its receptor and influences its clearance. By contrast, IGF-1 LR3’s modifications enable it to largely bypass this sequestration, resulting in a higher proportion of the analog being available to bind to the IGF-1 receptor and initiate signaling. This enhanced “free” fraction translates to a substantially longer duration of action and a more potent effect compared to equimolar concentrations of native IGF-1 in many experimental models. This property is invaluable for researchers investigating sustained activation of anabolic pathways or prolonged cellular responses, such as those related to cellular repair, hypertrophy, or anti-apoptotic mechanisms, providing a more consistent stimulus over time. The extensive research utilizing this analog is reflected in its dedicated research page.
From a pharmacological perspective, IGF-1 LR3 is classified as a long-acting IGF-1 analog, a characteristic that makes it particularly suitable for chronic or sustained stimulation studies in preclinical models. Its extended half-life means that a single administration can elicit biological effects for a prolonged period, reducing the frequency of dosing required in animal studies and offering a more stable experimental environment for observing downstream cellular and physiological changes. This contrasts sharply with native IGF-1, which typically exhibits a shorter half-life and more transient effects due to its rapid association with IGFBPs and subsequent clearance. The enhanced stability and bioavailability of IGF-1 LR3 contribute to its reproducibility and predictability as a research tool, allowing investigators to more reliably interpret dose-response relationships and time-dependent effects across diverse experimental designs.
The strategic modifications in IGF-1 LR3 effectively transform it into a robust tool for investigating the direct consequences of IGF-1 receptor activation. Researchers employ IGF-1 LR3 to explore fundamental questions in fields such as muscle physiology, neuroscience, and cellular senescence, where the sustained activation of IGF-1R signaling is critical. For instance, in studies of muscle hypertrophy or regeneration, the prolonged activity of IGF-1 LR3 can facilitate the observation of long-term anabolic responses, satellite cell activation, and improvements in tissue integrity. Similarly, in aging research, its sustained presence allows for the assessment of chronic pathway modulation on cellular viability, mitochondrial function, and the attenuation of age-related cellular pathologies. Its consistent performance profile, validated across 44 PubMed publications, underscores its reliability as a preferred IGF-1 analog for rigorous scientific inquiry. For researchers requiring high-quality IGF-1 LR3, understanding these structural and pharmacological attributes is paramount for successful experimental design.
Mechanism of Action: IGF-1 LR3 and IGF-1 Receptor Signaling Pathways
The mechanism of action for IGF-1 LR3 largely mirrors that of endogenous IGF-1, primarily through its binding and activation of the Insulin-like Growth Factor 1 Receptor (IGF-1R). The IGF-1R is a transmembrane receptor tyrosine kinase, a critical component of the cell surface that transduces extracellular signals into intracellular responses. Upon the binding of IGF-1 LR3 to the extracellular alpha subunits of the IGF-1R, a conformational change occurs, leading to the autophosphorylation of tyrosine residues within the intracellular beta subunits of the receptor. This autophosphorylation event serves as the crucial initiating step, creating docking sites for various intracellular signaling proteins containing Src homology 2 (SH2) domains. These adaptor proteins, most notably the Insulin Receptor Substrate (IRS) proteins (IRS-1 and IRS-2), become phosphorylated themselves, subsequently recruiting and activating a cascade of downstream effectors that orchestrate the diverse biological outcomes attributed to IGF-1 signaling.
Key Downstream Signaling Pathways
The activation of IRS proteins by the autophosphorylated IGF-1R leads to the recruitment and activation of two principal intracellular signaling pathways: the Phosphatidylinositol 3-Kinase (PI3K)/Akt/mTOR pathway and the Mitogen-Activated Protein Kinase (MAPK)/ERK pathway. These pathways are central to mediating the anabolic, anti-apoptotic, and mitogenic effects of IGF-1 LR3. The PI3K/Akt/mTOR pathway is predominantly responsible for promoting protein synthesis, cell growth, and survival. Upon activation, PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3), which then recruits and activates Akt (also known as Protein Kinase B). Akt, a serine/threonine kinase, has numerous downstream targets, including glycogen synthase kinase-3 (GSK-3), FoxO transcription factors, and the mammalian target of rapamycin (mTOR), which collectively regulate metabolism, cell proliferation, and apoptosis.
Concurrently, the MAPK/ERK pathway is engaged, playing a significant role in mediating cellular proliferation and differentiation. This pathway is initiated when IRS proteins activate Growth Factor Receptor-Bound protein 2 (Grb2) and Son of Sevenless (Sos), leading to the activation of Ras, a small GTPase. Activated Ras then sequentially activates a series of kinases: Raf, MEK (MAPK/ERK kinase), and finally ERK (Extracellular signal-Regulated Kinase) 1 and 2. Activated ERK translocates to the nucleus, where it phosphorylates various transcription factors, influencing gene expression patterns that drive cell cycle progression and differentiation. The coordinated activation of both the PI3K/Akt/mTOR and MAPK/ERK pathways by IGF-1 LR3 ensures a comprehensive cellular response, allowing researchers to study how these pathways interact to regulate complex biological phenomena. For more detailed information on specific mechanisms, researchers may consult dedicated resources on IGF-1 LR3’s mechanism of action.
The prolonged bioavailability of IGF-1 LR3 due to its reduced IGFBP binding means that it can sustain the activation of these critical signaling pathways for a longer duration compared to native IGF-1. This sustained activation is particularly advantageous in research models where chronic pathway engagement is required to observe robust phenotypic changes, such as in studies of muscle hypertrophy, tissue regeneration, or the prevention of cellular atrophy. For example, sustained Akt activation can lead to prolonged phosphorylation of mTOR, driving protein synthesis over extended periods. Similarly, prolonged ERK activation can maintain gene expression profiles conducive to sustained cell proliferation or differentiation. Understanding these sustained effects is vital for interpreting experimental results and designing effective research protocols in fields ranging from sports science to gerontology, where long-term cellular adaptation is a primary focus.
Role of IGF-1 LR3 in Protein Synthesis and Cellular Proliferation Studies
IGF-1 LR3, as a potent activator of the IGF-1 receptor, plays a critical role in promoting two fundamental cellular processes: protein synthesis and cellular proliferation. These activities are central to tissue growth, repair, and maintenance, making IGF-1 LR3 an invaluable tool for researchers investigating the mechanisms underlying anabolism and cellular dynamics. The primary pathway mediating these effects is the PI3K/Akt/mTOR axis, which, upon activation by IGF-1 LR3, orchestrates a series of events leading to increased translational efficiency and cell cycle progression. Understanding how IGF-1 LR3 influences these processes at a molecular level is crucial for dissecting its broader biological impacts in various experimental models, from skeletal muscle research to studies on tissue regeneration and cellular aging.
Induction of Protein Synthesis
The stimulatory effect of IGF-1 LR3 on protein synthesis is a cornerstone of its anabolic actions. Following IGF-1R activation, the PI3K/Akt pathway is robustly engaged, leading to the phosphorylation and activation of Akt. Activated Akt, in turn, phosphorylates and inhibits key negative regulators of protein synthesis, most notably Tuberous Sclerosis Complex 2 (TSC2) and Glycogen Synthase Kinase 3 beta (GSK-3β). Inhibition of TSC2 releases its suppression on the mammalian Target of Rapamycin Complex 1 (mTORC1), thereby activating mTORC1. mTORC1 is a master regulator of protein synthesis, controlling ribosomal biogenesis and translation initiation. Its activation leads to the phosphorylation of two crucial downstream targets: ribosomal protein S6 kinase (S6K1) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). Phosphorylation of S6K1 enhances ribosomal biogenesis and the translation of specific mRNAs, while phosphorylation of 4E-BP1 liberates eukaryotic initiation factor 4E (eIF4E), allowing it to form the eIF4F complex, which is essential for cap-dependent translation initiation. The net result is a significant increase in the rate of protein synthesis, contributing to cellular hypertrophy and tissue accretion.
Beyond direct protein synthesis, IGF-1 LR3 also modulates protein degradation pathways, contributing to a net anabolic state. For instance, Akt activation can inhibit the activity of FoxO transcription factors, which are known to upregulate the expression of genes involved in proteasomal degradation and autophagy, such as muscle atrophy F-box (MAFbx/atrogin-1) and muscle ring finger 1 (MuRF1). By suppressing these catabolic pathways while simultaneously enhancing protein synthesis, IGF-1 LR3 promotes a favorable balance towards protein accretion in cells and tissues. This dual action makes it a powerful experimental tool for researchers studying conditions characterized by muscle wasting, cachexia, or age-related sarcopenia, allowing for the investigation of strategies to counteract protein loss and support cellular growth.
Promotion of Cellular Proliferation
In addition to its role in protein synthesis, IGF-1 LR3 is a potent mitogen, stimulating cellular proliferation through the concerted activation of both the PI3K/Akt and MAPK/ERK pathways. The MAPK/ERK pathway, particularly, is a key driver of cell cycle progression. As described previously, IGF-1R activation leads to the recruitment of Grb2/Sos and subsequent activation of the Ras-Raf-MEK-ERK cascade. Activated ERK phosphorylates various cytosolic and nuclear targets, including transcription factors (e.g., Elk-1, c-Myc) and cell cycle regulators (e.g., cyclins, cyclin-dependent kinases, CDK inhibitors). These events collectively promote the transition of cells from the G1 to the S phase of the cell cycle, leading to DNA synthesis and subsequent cell division.
The proliferative effects of IGF-1 LR3 are critical in research areas focused on tissue repair, regeneration, and developmental biology. For example, in muscle tissue, IGF-1 LR3 has been shown to stimulate the proliferation of satellite cells, which are adult muscle stem cells essential for muscle repair and hypertrophy. In studies involving fibroblasts, endothelial cells, and chondrocytes, IGF-1 LR3 can enhance their proliferation, contributing to processes like wound healing, angiogenesis, and cartilage repair. Its capacity to sustain both protein synthesis and cellular proliferation makes IGF-1 LR3 an indispensable reagent for investigating the intricate mechanisms that govern tissue growth, cellular repair, and the maintenance of tissue homeostasis in various physiological and pathophysiological contexts. Researchers rely on the quality testing and Certificate of Analysis to ensure the reliability of such critical research compounds.
Investigating Anabolic Pathways with IGF-1 LR3: mTOR and Beyond
The mammalian Target of Rapamycin (mTOR) pathway stands as a central regulatory hub for cellular anabolism, integrating signals from growth factors, nutrients, energy status, and stress to control cell growth, proliferation, and survival. IGF-1 LR3, by virtue of its robust activation of the IGF-1 receptor, serves as a powerful research tool for dissecting the complexities of the mTOR pathway and its downstream effectors. The sustained activation profile of IGF-1 LR3 allows for comprehensive studies into how prolonged IGF-1 signaling influences mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2) activities, and subsequently, the anabolic responses of various cell types and tissues. Understanding these interactions is vital for researchers exploring muscle hypertrophy, tissue regeneration, metabolic regulation, and the molecular underpinnings of cellular aging.
mTORC1 Activation and Protein Synthesis Regulation
IGF-1 LR3 primarily activates mTORC1 through the PI3K/Akt pathway. Upon IGF-1R stimulation, Akt phosphorylates and inhibits the TSC1/TSC2 complex. This inhibition liberates Rheb (Ras homolog enriched in brain) from its GTPase-activating protein (GAP) activity, allowing Rheb to accumulate in its GTP-bound state, which directly activates mTORC1. Once activated, mTORC1 phosphorylates key downstream targets that orchestrate protein synthesis. These include S6 kinase 1 (S6K1), which promotes ribosomal biogenesis and translation of specific mRNAs encoding ribosomal proteins and elongation factors, and 4E-binding protein 1 (4E-BP1), whose phosphorylation releases eIF4E, thereby facilitating cap-dependent translation initiation. By utilizing IGF-1 LR3, researchers can precisely investigate the temporal dynamics and magnitude of mTORC1 activation, examining its impact on global protein synthesis rates, mRNA translation profiles, and the subsequent cellular hypertrophic responses in models ranging from isolated myotubes to whole animal studies of muscle growth.
Beyond its direct role in promoting protein synthesis, mTORC1, through its downstream effectors, also influences other anabolic processes and inhibits catabolic pathways. For instance, activated S6K1 can provide negative feedback to the IGF-1R and IRS-1, modulating the sensitivity of cells to growth factor stimulation. Moreover, mTORC1 is a critical regulator of autophagy, a cellular recycling process. High mTORC1 activity, as stimulated by IGF-1 LR3, typically inhibits autophagy, thereby preserving cellular components and contributing to a net anabolic state. Research employing IGF-1 LR3 allows for the examination of this interplay, providing insights into how growth factor signaling coordinates nutrient utilization and cellular turnover. Such investigations are crucial for understanding conditions like sarcopenia, where a decline in mTORC1 signaling and an increase in catabolism contribute to muscle mass loss.
Beyond mTOR: Exploring Other Anabolic Pathways
While mTOR is a major player, IGF-1 LR3’s influence extends to other anabolic and anti-catabolic pathways, providing a comprehensive framework for research into cellular anabolism. One significant area of investigation involves the modulation of the ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway, which are the primary systems for protein degradation. As mentioned, Akt activation by IGF-1 LR3 can inhibit FoxO transcription factors, which are known to upregulate genes encoding E3 ubiquitin ligases (e.g., MAFbx/atrogin-1, MuRF1) and autophagy-related proteins. By suppressing the expression of these catabolic genes, IGF-1 LR3 contributes to a reduction in protein breakdown, further augmenting its anabolic effect. Researchers can utilize IGF-1 LR3 to study the intricate balance between protein synthesis and degradation, providing insights into muscle wasting disorders and the maintenance of cellular proteostasis.
Furthermore, IGF-1 LR3 signaling influences satellite cell activation and differentiation, which are crucial for muscle repair and growth. IGF-1 stimulates quiescent satellite cells to proliferate and differentiate, fusing with existing muscle fibers to promote hypertrophy or forming new fibers. This process involves the upregulation of specific myogenic regulatory factors (MRFs) such as
Frequently Asked Questions
What is IGF-1 LR3 and how does it differ from native IGF-1 in research applications?
IGF-1 LR3, or Long R3 IGF-1, is a long-acting analog of insulin-like growth factor 1. Its key differences from native IGF-1 include an Arg3 substitution and a 13-amino acid N-terminal extension, which collectively reduce its affinity for IGF binding proteins (IGFBPs) and extend its half-life in research systems, allowing for sustained IGF-1 receptor activation.
How does IGF-1 LR3 interact with the IGF-1 receptor?
IGF-1 LR3 binds with high affinity to the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase. Upon binding, it induces autophosphorylation of the receptor, initiating intracellular signaling cascades such as the PI3K/Akt/mTOR and MAPK/ERK pathways, which are critical for cellular growth and anabolic processes.
What are the primary signaling pathways investigated using IGF-1 LR3 in cellular models?
In cellular research models, IGF-1 LR3 is primarily used to investigate the PI3K/Akt/mTOR pathway, which is a central regulator of protein synthesis, cell growth, and metabolism. It also plays a significant role in studies exploring the MAPK/ERK pathway, involved in cell proliferation and differentiation.
Why is IGF-1 LR3 considered a ‘long-acting’ analog for research?
IGF-1 LR3 is considered long-acting because its modified structure (Arg3 substitution and N-terminal extension) significantly reduces its binding to IGF binding proteins (IGFBPs) compared to native IGF-1. This reduction in IGFBP binding leads to a prolonged bioavailability and extended half-life within research systems, allowing for sustained receptor activation.
Are there specific *in vitro* models where IGF-1 LR3 research is particularly relevant?
IGF-1 LR3 research is highly relevant in various *in vitro* models, including primary cell cultures (e.g., myoblasts, fibroblasts, osteoblasts) and established cell lines used to study muscle protein synthesis, bone remodeling, neural cell survival, and general cellular proliferation and differentiation mechanisms.
What analytical methods are commonly employed to study the effects of IGF-1 LR3 in research samples?
Common analytical methods include Western blotting to assess protein phosphorylation and expression levels of key signaling molecules (e.g., Akt, mTOR, S6K1), RT-qPCR for gene expression analysis, ELISA for quantifying protein levels, cell proliferation assays (e.g., MTT, BrdU incorporation), and immunofluorescence for subcellular localization studies.
Can IGF-1 LR3 be used as a research tool to study muscle protein synthesis?
Yes, IGF-1 LR3 is a widely utilized research tool for studying muscle protein synthesis. Its potent activation of the PI3K/Akt/mTOR pathway in muscle cell cultures and *in vivo* animal models makes it invaluable for investigating the molecular mechanisms underlying muscle growth, repair, and potential mitigation of muscle atrophy in preclinical studies.
What precautions should researchers take when handling IGF-1 LR3 for laboratory use?
Researchers should adhere to standard laboratory safety protocols when handling IGF-1 LR3, including wearing appropriate personal protective equipment (gloves, lab coat, eye protection) and working in a well-ventilated area. Proper storage conditions (e.g., specified temperature, reconstitution guidelines) are crucial to maintain compound stability and potency for experimental integrity.
Scientific References
All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.